Novartis grabs kidney drug developer Regulus in $1.7bn deal

Novartis to buy Regulus Therapeutics for as much as $1.7 billion

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire Regulus Therapeutics, a local company on the cusp of bringing a potential breakthrough treatment for kidney disease onto the market. In a deal with total equity value of up to $1.7 billion, a subsidiary of Novartis will merge with Regulus in an offer that is expected to close in the second half of this year. Among the medicines …

Novartis grabs kidney drug developer Regulus in $1.7bn deal

Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug

Novartis to buy kidney-focused biotech built around Nobel-winning discovery for $800 million

The deal, which includes another $900 million in milestone payments, could help Novartis expand its burgeoning kidney disease line.

Novartis to acquire Regulus in deal for kidney disease drug

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance microRNA technology.

Novartis to acquire Regulus in $1.7B kidney drug deal

The basics: Novartis to acquire Regulus for up to $1.7 billion Deal adds ADPKD candidate farabursen to pipeline Target brings proprietary microRNA drug platform Novartis plans to acquire clinical stage biotech Regulus Therapeutics in a deal worth up to $1.7 billion. Under the terms announced April 30, the Swiss drugmaker will make an upfront payment of $800 million to the San Diego-based company. If Regulus’ lead drug candidate, farabursen, get…